Item 8.01. Other Events
On March 16, 2025 (the “Effective Date”), GoodRx Holdings, Inc. (the “Company”) entered into three Stock
Purchase Agreements: (a) one with Spectrum Equity VII, L.P., Spectrum VII Investment Managers’ Fund, L.P.,
and Spectrum VII Co-Investment Fund, L.P. (collectively, “Spectrum”), (b) one with Francisco Partners IV, L.P.
and Francisco Partners IV-A (collectively, “Francisco Partners”) and (c) one with Idea Men, LLC (“Idea Men”).
Pursuant to such agreements, the Company agreed to repurchase 3,000,000 shares, 10,000,000 shares and
7,000,000 shares of the Company’s Class A common stock (after giving effect to the automatic conversion of
the Company’s Class B common stock to Class A common stock upon such repurchase) from Spectrum,
Francisco Partners and Idea Men, respectively, at a price of $4.20 per share, in each case representing a
discount from the Company’s closing share price of $4.42 as of the last trading day prior to the Effective Date
(the “March 2025 Repurchase”), as part of the Company’s existing authority to repurchase up to an aggregate
of $450.0 million of its Class A common stock (the “Repurchase Program”). Approximately $198.3 million is
expected to remain available under the Repurchase Program following the March 2025 Repurchase. This
estimate is inclusive of estimated direct costs associated with these transactions but exclusive of estimated
excise taxes that may be associated with these transactions. The March 2025 Repurchase is expected to close
on or about March 21, 2025, subject to customary closing conditions.
In connection with the March 2025 Repurchase, each of Spectrum, Francisco Partners and Idea Men, together
with their respective affiliates, have agreed that they will not, without the Company’s prior approval, sell,
transfer, otherwise dispose of or enter into a hedging transaction involving the Company's securities until the
completion of the second full trading day after the public release of earnings data for the quarter ended March
31, 2025.
Forward-Looking Statements
This Current Report on Form 8-K (“Form 8-K”) contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements contained in this Form 8-K that do not relate to
matters of historical fact should be considered forward-looking statements, including without limitation
statements regarding the amount available under the Repurchase Program following the March 2025
Repurchase and the anticipated closing of the March 2025 Repurchase. These statements are neither promises
nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause
the Company’s actual results, performance or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking statements, including, but not limited
to, the important factors discussed in the sections entitled “Risk Factors” of the Company’s Annual Report on
Form 10-K for the fiscal year ended December 31, 2024, and in its other filings with the Securities and
Exchange Commission. The forward-looking statements in this Form 8-K are based upon information available
to the Company as of the date of this Form 8-K, and while the Company believes such information forms a
reasonable basis for such statements, such information may be limited or incomplete, and the statements
should not be read to indicate that the Company has conducted an exhaustive inquiry into, or review of, all
potentially available relevant information. These statements are inherently uncertain and investors are
cautioned not to unduly rely upon these statements. While the Company may elect to update such forward-
looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events
cause its views to change.